Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
strategic options
Biotech
Cellectar seeks strategic alternatives, sinking stock
Radiopharma biotech Cellectar is seeking strategic alternatives after attempting to partner off its sole clinical-stage asset this winter.
Gabrielle Masson
Apr 30, 2025 10:41am
Elevation faces activist investor demands to wind down
Apr 17, 2025 10:00am
Adaptimmune questions own longevity, axes preclinical funding
Mar 20, 2025 2:04pm
Struggling Relmada pays $3M for Tourette's asset from Asarina
Feb 7, 2025 11:00am
After 3rd phase 3 strike, Relmada's depression drug is out
Dec 9, 2024 2:30pm
Portage Biotech hints at potential closure as it halts programs
Apr 12, 2024 10:22am
